Literature DB >> 26176396

Clostridium difficile Infection.

Daniel A Leffler, J Thomas Lamont.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26176396     DOI： 10.1056/NEJMc1506004

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  80 in total

1.  Hospital Impact After a Chemical Spill That Compromised the Potable Water Supply: West Virginia, January 2014.

Authors:  Joy Hsu; Maria C Del Rosario; Erica Thomasson; Danae Bixler; Loretta Haddy; Mary Anne Duncan
Journal:  Disaster Med Public Health Prep       Date:  2017-03-06       Impact factor: 1.385

2.  Faecal lactoferrin and calprotectin in patients with Clostridium difficile infection: a case-control study.

Authors:  F Barbut; C Gouot; N Lapidus; L Suzon; R Syed-Zaidi; V Lalande; C Eckert
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-08-12       Impact factor: 3.267

3.  Colon Surgery Risk With Corticosteroids Versus Immunomodulators or Biologics in Inflammatory Bowel Disease Patients With Clostridium difficile Infection.

Authors:  Dipesh Solanky; Darrell S Pardi; Edward V Loftus; Sahil Khanna
Journal:  Inflamm Bowel Dis       Date:  2019-02-21       Impact factor: 5.325

4.  Quantitative and synthetic biology approaches to combat bacterial pathogens.

Authors:  Feilun Wu; Jonathan H Bethke; Meidi Wang; Lingchong You
Journal:  Curr Opin Biomed Eng       Date:  2017-10-24

5.  Gut microbiome predictors of treatment response and recurrence in primary Clostridium difficile infection.

Authors:  Sahil Khanna; Emmanuel Montassier; Bradley Schmidt; Robin Patel; Daniel Knights; Darrell S Pardi; Purna Kashyap
Journal:  Aliment Pharmacol Ther       Date:  2016-08-02       Impact factor: 8.171

6.  Predictive factors, outcomes, and molecular epidemiology of Clostridioides difficile diarrhea in Brazilian hospitals.

Authors:  Evelyne Santana Girão; Bruno de Melo Tavares; Sania Alves Dos Santos; Gessica Lorena Gamarra; Camila Rizek; Roberta Cristina Martins; Lauro Vieira Perdigão Neto; Constancia Diogo; Tatiana D' Annibale Orsi; Hugo Manuel Paz Morales; Keite da Silva Nogueira; Adriane Ceshin Maestri; Icaro Boszczowski; Filipe Piastrelli; Cecilia Leite Costa; Daniely Viana Costa; Geovania Maciel; Janete Romão; Thais Guimarães; Gerly Anne de Castro Brito; Silvia Figueiredo Costa
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2021-03-30       Impact factor: 3.267

7.  Nucleic Acid Amplification Test Quantitation as Predictor of Toxin Presence in Clostridium difficile Infection.

Authors:  M J T Crobach; N Duszenko; E M Terveer; C M Verduin; E J Kuijper
Journal:  J Clin Microbiol       Date:  2018-02-22       Impact factor: 5.948

8.  Phase 1 Study To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Oral Doses of DS-2969b, a Novel GyrB Inhibitor, in Healthy Subjects.

Authors:  Alexander G Vandell; Satoshi Inoue; Justin Dennie; Yasuo Nagasawa; Roohi Gajee; Joe Pav; George Zhang; Cynthia Zamora; Nobuhisa Masuda; Giorgio Senaldi
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

Review 9.  Fecal microbiota transplantation in inflammatory bowel disease: the quest for the holy grail.

Authors:  B Pigneur; H Sokol
Journal:  Mucosal Immunol       Date:  2016-07-27       Impact factor: 7.313

10.  Fecal Microbiota Transplant in Patients With Recurrent Clostridium Difficile Infection.

Authors:  Stefan Hagel; Anne Fischer; Philipp Ehlermann; Thorsten Frank; Kester Tueffers; Andreas Sturm; Alexander Link; Muenevver Demir; Arno Siebenhaar; Martin Storr; Thomas Glueck; Erhard Siegel; Philip Solbach; Felix Goeser; Christian B. Koelbel; Ansgar Lohse; Christoph Luebbert; Ulrich Kandzi; Matthias Maier; Stefanie Schuerle; Markus M. Lerch; Daniela Tacke; Oliver A. Cornely; Andreas Stallmach; Maria Vehreschild
Journal:  Dtsch Arztebl Int       Date:  2016-09-05       Impact factor: 5.594
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.